# Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel

> **NCT00989300** · PHASE1 · COMPLETED · sponsor: **Janssen Cilag S.A.S.** · enrollment: 39 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treatment A - rabeprazole
- **DRUG:** Treatment B - omeprazole
- **OTHER:** Treatment C - placebo

## Key facts

- **NCT ID:** NCT00989300
- **Lead sponsor:** Janssen Cilag S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2012-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989300, "Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00989300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*